Owning the Cancer Treatment and the Plant

Owning the Cancer Treatment and the Plant

For two decades, commercial use of raw acidic cannabinoids sat inside a corporate patent claim. That patent has now expired. But the cancer‑treatment patent built on top of it remains in force, shaping who gets to turn a plant into medicine — and who gets left outside the system.

Commercial patents shaped the medical uses of the same plant people grew freely — and they still govern its cancer treatments.

Beneath the headlines about law reform for the Cannabis genus lies a quieter story — about patents, ownership, and the legal mechanism that allows corporations to claim exclusive rights over medical uses of the same plant ordinary people grow for themselves.

To understand how we got here, we follow two key patents:

  • one that has expired, and
  • one that still governs the future of plant‑based cancer care.

Together, they reveal how the medical system decides what counts as “medicine,” who is allowed to make it, and who is permitted to profit from it.

🧩 Before We Begin: What a Patent Actually Covers

A patent does not grant ownership of a plant. It grants exclusive rights to specific medical uses, formulations, or extraction methods for a limited time.

This distinction matters — and it’s central to understanding the report that follows.

1. The First Fence: Acidic Cannabinoids (Expired March 2026)

For twenty years, US7807711 covered the medical use of acidic cannabinoids — THC‑A, CBDA, CBGA and other raw, non‑decarboxylated compounds — for treating inflammation, autoimmune disease, pain, MS, IBD, skin disorders, and symptom relief in cancer.

These are the compounds you encounter when you:

  • juice leaves
  • make raw tinctures
  • use fresh flower
  • avoid heating your Cannabis

In other words, the plant as you grow it.

Home growers were never the target of enforcement. But in the commercial and clinical world, this patent shaped:

  • what could be developed
  • what could be licensed
  • what could be sold
  • what doctors could prescribe

The patent expired in March 2026. The plant didn’t change. Only the legal boundary around its medical uses did.

2. The Second Fence: Phytocannabinoids in Cancer Treatment (Still Active)

The second patent, US20130059018, remains active. It claims the use of phytocannabinoids — THC, CBD, CBG, CBC, THCV and botanical drug substances — for treating cancers, including:

  • prostate
  • breast
  • colon
  • glioma
  • metastatic disease

This patent’s current assignee is Jazz Pharmaceuticals, the company that absorbed GW Pharma, the original developer of Sativex.

It is broad. It is commercially significant. And unlike the acidic‑cannabinoid patent, it has not expired.

This means that while the raw plant is now legally “free,” the cancer‑treatment applications of that plant remain restricted behind corporate Intellectual Property or IP.

3. The Trial That Was Meant to Validate the Patent — And Didn’t

In 2021, Jazz announced a major Phase 2 trial — ARISTOCRAT — testing Sativex with temozolomide in recurrent glioblastoma.

Early Phase 1 data looked promising. There was genuine hope.

But in late 2023, the results were released:

  • The study did not show a statistically significant improvement in overall survival.
  • It did not improve progression‑free survival.
  • It did not demonstrate clinical benefit.

The trial failed.

Yet the patent remains.

Why? Because patents are granted based on novelty and plausibility at the time of filing, not on whether later clinical trials succeed.

Holding a patent does not guarantee a drug will reach the market. It guarantees exclusivity only if a treatment is eventually proven effective and approved.

4. A Wider Scientific Picture

The ARISTOCRAT trial is one data point — an important one, but not the whole story. Cannabis and cancer research didn’t begin with that study, and it doesn’t end with it.

For more than two decades, preclinical research has shown consistent anti‑tumour effects across multiple cancer models. Studies have demonstrated:

  • apoptosis (programmed tumour cell death)
  • autophagy‑related cell death
  • reduced tumour proliferation
  • anti‑angiogenic effects (reduced blood supply to tumours)
  • synergy with chemotherapy agents such as temozolomide

These findings come from cell‑line research and animal models, where cannabinoids have repeatedly shown the ability to disrupt tumour growth through multiple biological pathways.

Early human evidence, while limited, points in the same direction. Small pilot studies in glioblastoma patients have reported reduced tumour cell proliferation following cannabinoid treatment — findings that align with the apoptosis and cell‑death mechanisms observed in preclinical models. These early signals do not claim cannabis is a cure, but they do reinforce that the biological rationale behind cannabinoid‑based cancer research remains strong.

The failure of one clinical trial does not invalidate the plant. It simply highlights how much research remains unexplored, restricted, or underfunded — and how much of the scientific landscape is still shaped by access, regulation, and who is permitted to study the plant in the first place.

5. How This Affected You If You Wanted to Grow Your Own

Now that the acidic‑cannabinoid patent has expired, we can speak plainly.

For twenty years, commercial use of raw acidic cannabinoids for a wide range of medical applications sat inside a corporate patent claim.

Home growers were never targeted. But the patent shaped the world around you:

  • which products appeared in pharmacies
  • which formulations were considered “legitimate”
  • what doctors could prescribe
  • what governments recognised as medicine

You were growing a plant. Corporations were claiming exclusive rights over certain medical uses of its chemistry.

And now that the patent has expired, nothing about your plant has changed. Only the legal boundary did.

Meanwhile, the cancer‑treatment patent remains active — meaning the system still draws a line between:

  • your plant, and
  • their medicine

Even when both are derived from the same flower.

Cannabis head

6. What These Patents Are Worth

We can’t assign a precise dollar value — companies don’t disclose that — but we can map the logic.

🧪 The expired acidic‑cannabinoid patent

Its value was historical:

  • It shaped early product development.
  • It influenced regulatory definitions of “non‑psychoactive Cannabis medicine.”
  • It created licensing opportunities.
  • It blocked competitors in key therapeutic categories.

💸 The active cancer‑treatment patent

Its value is speculative but substantial.

The commercial potential is not hypothetical. Cannabinoid pharmaceuticals such as Epidiolex and Sativex have already generated hundreds of millions in global revenue.

Even a single approved cannabinoid‑based adjunct therapy in a niche cancer could generate:

  • hundreds of millions per year in revenue
  • billions in net present value over exclusivity

This is why the patent remains strategically important despite the ARISTOCRAT trial’s failure. It preserves option value — the right to profit if future science is successful.

Patents do not require clinical proof — only a plausible scientific claim at the time of filing.

generic oral-spray bottle

7. Two Pathways for Cannabis Medicine

Today, two parallel pathways exist:

🌿 The Herbal Commons

  • Home cultivation
  • Whole‑plant preparations
  • Informal knowledge networks
  • Low‑cost access

💊 The Pharmaceutical Pathway

  • Standardised extracts
  • Patented formulations
  • Clinical trials and regulatory approval
  • High development costs

One pathway is ancient and communal. The other is modern and commercial.

But these pathways don’t exist in isolation. They sit inside a broader global trend we’ve already documented in Treaty Troubles Ahead with US Crackdown on Hemp:

“The U.S. government is systematically eliminating a parallel market that bypasses its preferred channels of state licensing, taxation, pharmaceutical pathways, and federal oversight. The state is reasserting a monopoly on control, using the treaty as its constitutional shield. This creates a dangerous global precedent where ‘regulation’ can seamlessly become ‘prohibition’ by tightening definitions.”

The same logic applies here.

When governments narrow the legal definition of “Cannabis,” “hemp,” “intoxicating,” or “medicinal use,” they aren’t just regulating plants — they’re regulating pathways:

  • who can grow
  • who can extract
  • who can formulate
  • who can prescribe
  • who can profit

Incoming U.S. legislation that seeks to redefine hemp, restrict cannabinoids, or collapse the distinction between “intoxicating” and “non‑intoxicating” compounds directly influences the future of both pathways:

  • It shrinks the Herbal Commons.
  • It fortifies the Pharmaceutical Pathway.
  • It aligns domestic law with the same treaty logic used to justify international control.

In this context, patents aren’t isolated corporate tools — they’re part of a larger architecture of enclosure. Definitions in law and definitions in IP reinforce each other, tightening the funnel through which Cannabis can legally move.

The result is simple:

The more the state narrows the definition of what Cannabis is, the more valuable corporate claims over what Cannabis does become.

One patent has expired. Another still stands.

The plant never changed. Only the legal boundaries around it did.

The question isn’t whether Cannabis works for cancer. The question is who gets ownership of the answer.

🔎 References

Cannabinoids and Cancer Research (Contextual)

Molecular Mechanisms Involved in the Antitumor Activity of Cannabinoids on Gliomas: Role for Oxidative Stress

Velasco, G., Sánchez, C., & Guzmán, M. (2012). Towards the Use of Cannabinoids as Antitumour Agents. Nature Reviews Cancer

Ladin, D. A. et al. (2016). Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents

Medical Cannabis: The Natural Herbal Option — Medical Cannabis is not a miracle cure. It is a natural herbal option that supports the body’s own regulatory systems.

✨ Topic Cluster

2. Legalisation Pathways & Structural Separation: Examining pathways to Cannabis legalisation, including descheduling, regulatory models, political incentives, and the structural reforms needed for a functional post‑prohibition system.

🏛️ Pillar Content

📌 Related Reports

👉 This Article

Owning the Cancer Treatment and the Plant — How expired patents, failed trials, and active claims still shape the future of cannabis‑based cancer treatment — and what this means for growers.

Share this article from here:
Tags